Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308188972> ?p ?o ?g. }
- W4308188972 endingPage "97" @default.
- W4308188972 startingPage "86" @default.
- W4308188972 abstract "Abstract Background Vemurafenib (VEM) is a commonly used inhibitor of papillary thyroid cancer (PTC) and melanoma with the BRAF V600E mutation; however, acquired resistance is unavoidable. The present study aimed to identify a potential target to reverse resistance. Materials and methods A VEM-resistant PTC cell line (B-CPAP/VR) was established by gradually increasing the drug concentration, and a VEM-resistant BRAF V600E melanoma cell line (A375/VR) was also established. RNA sequencing and bioinformatics analyses were conducted to identify dysregulated genes and construct a transcription factor (TF) network. The role of a potential TF, forkhead box P2 (FOXP2), verified by qRT-PCR, was selected for further confirmation. Results The two resistant cell lines were tolerant of VEM and displayed higher migration and colony formation abilities ( p < 0.05). RNA sequencing identified 9177 dysregulated genes in the resistant cell lines, and a TF network consisting of 13 TFs and 44 target genes was constructed. Alterations in FOXP2 expression were determined to be consistent between the two VEM-resistant cell lines. Finally, silencing FOXP2 resulted in an increase in drug sensitivity and significant suppression of the migration and colony formation abilities of the two resistant cell lines ( p < 0.05). Conclusions The present study successfully established two VEM-resistant cell lines and identified a potential target for VEM-resistant PTC or melanoma." @default.
- W4308188972 created "2022-11-09" @default.
- W4308188972 creator A5001642071 @default.
- W4308188972 creator A5009528787 @default.
- W4308188972 creator A5039632895 @default.
- W4308188972 creator A5041006322 @default.
- W4308188972 creator A5050928628 @default.
- W4308188972 creator A5076480463 @default.
- W4308188972 creator A5087298250 @default.
- W4308188972 date "2022-11-04" @default.
- W4308188972 modified "2023-09-28" @default.
- W4308188972 title "Silencing FOXP2 reverses vemurafenib resistance in BRAFV600E mutant papillary thyroid cancer and melanoma cells" @default.
- W4308188972 cites W1933537883 @default.
- W4308188972 cites W1970314237 @default.
- W4308188972 cites W1971947883 @default.
- W4308188972 cites W1982393730 @default.
- W4308188972 cites W1991572775 @default.
- W4308188972 cites W1998134241 @default.
- W4308188972 cites W2062871120 @default.
- W4308188972 cites W2086802511 @default.
- W4308188972 cites W2097539881 @default.
- W4308188972 cites W2130662884 @default.
- W4308188972 cites W2143222157 @default.
- W4308188972 cites W2185718064 @default.
- W4308188972 cites W2271763089 @default.
- W4308188972 cites W2346104069 @default.
- W4308188972 cites W2403459350 @default.
- W4308188972 cites W2472679117 @default.
- W4308188972 cites W2475168395 @default.
- W4308188972 cites W2503674037 @default.
- W4308188972 cites W2745340115 @default.
- W4308188972 cites W2790904299 @default.
- W4308188972 cites W2922772115 @default.
- W4308188972 cites W2938062190 @default.
- W4308188972 cites W2950035368 @default.
- W4308188972 cites W2974851393 @default.
- W4308188972 cites W2995695305 @default.
- W4308188972 cites W2996359940 @default.
- W4308188972 cites W3125909479 @default.
- W4308188972 cites W3128111499 @default.
- W4308188972 cites W3130125229 @default.
- W4308188972 cites W3131437058 @default.
- W4308188972 cites W3154289416 @default.
- W4308188972 cites W4221066541 @default.
- W4308188972 cites W4229363926 @default.
- W4308188972 cites W4244963342 @default.
- W4308188972 cites W4281688197 @default.
- W4308188972 doi "https://doi.org/10.1007/s12020-022-03180-y" @default.
- W4308188972 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36331719" @default.
- W4308188972 hasPublicationYear "2022" @default.
- W4308188972 type Work @default.
- W4308188972 citedByCount "2" @default.
- W4308188972 countsByYear W43081889722023 @default.
- W4308188972 crossrefType "journal-article" @default.
- W4308188972 hasAuthorship W4308188972A5001642071 @default.
- W4308188972 hasAuthorship W4308188972A5009528787 @default.
- W4308188972 hasAuthorship W4308188972A5039632895 @default.
- W4308188972 hasAuthorship W4308188972A5041006322 @default.
- W4308188972 hasAuthorship W4308188972A5050928628 @default.
- W4308188972 hasAuthorship W4308188972A5076480463 @default.
- W4308188972 hasAuthorship W4308188972A5087298250 @default.
- W4308188972 hasBestOaLocation W43081889721 @default.
- W4308188972 hasConcept C104317684 @default.
- W4308188972 hasConcept C119056186 @default.
- W4308188972 hasConcept C121608353 @default.
- W4308188972 hasConcept C2776131300 @default.
- W4308188972 hasConcept C2777658100 @default.
- W4308188972 hasConcept C2779761222 @default.
- W4308188972 hasConcept C2781461381 @default.
- W4308188972 hasConcept C2994587330 @default.
- W4308188972 hasConcept C502942594 @default.
- W4308188972 hasConcept C54355233 @default.
- W4308188972 hasConcept C81885089 @default.
- W4308188972 hasConcept C86803240 @default.
- W4308188972 hasConceptScore W4308188972C104317684 @default.
- W4308188972 hasConceptScore W4308188972C119056186 @default.
- W4308188972 hasConceptScore W4308188972C121608353 @default.
- W4308188972 hasConceptScore W4308188972C2776131300 @default.
- W4308188972 hasConceptScore W4308188972C2777658100 @default.
- W4308188972 hasConceptScore W4308188972C2779761222 @default.
- W4308188972 hasConceptScore W4308188972C2781461381 @default.
- W4308188972 hasConceptScore W4308188972C2994587330 @default.
- W4308188972 hasConceptScore W4308188972C502942594 @default.
- W4308188972 hasConceptScore W4308188972C54355233 @default.
- W4308188972 hasConceptScore W4308188972C81885089 @default.
- W4308188972 hasConceptScore W4308188972C86803240 @default.
- W4308188972 hasIssue "1" @default.
- W4308188972 hasLocation W43081889721 @default.
- W4308188972 hasLocation W43081889722 @default.
- W4308188972 hasLocation W43081889723 @default.
- W4308188972 hasOpenAccess W4308188972 @default.
- W4308188972 hasPrimaryLocation W43081889721 @default.
- W4308188972 hasRelatedWork W1921841920 @default.
- W4308188972 hasRelatedWork W2328771497 @default.
- W4308188972 hasRelatedWork W2619622310 @default.
- W4308188972 hasRelatedWork W2790628335 @default.
- W4308188972 hasRelatedWork W2790945713 @default.
- W4308188972 hasRelatedWork W2945942726 @default.